MyoKardia Announces HCM Program Updates: Accelerates Timing for Mavacamten Topline Phase 3 Data; Re-acquires U.S. Royalty Rights to HCM Programs from Sanofi
18 juil. 2019 08h30 HE
|
MyoKardia, Inc.
EXPLORER-HCM Patient Screening Closes Ahead of Schedule – Initial Results Now Anticipated in the Second Quarter of 2020 Royalty Purchase Creates Additional Economic Value for MyoKardia’s Emerging HCM...
MyoKardia Publishes Data in Nature Digital Medicine Showing Potential of Wrist-Worn Biosensor to Screen for Hypertrophic Cardiomyopathy
24 juin 2019 08h30 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 24, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK) today announced the publication of an article titled, “Machine Learning Detection of Obstructive...
MyoKardia to Present at 2019 BMO Prescriptions for Success Healthcare Conference
18 juin 2019 16h05 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., June 18, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...
MyoKardia Presents Results from Phase 1a Clinical Trial of MYK-491 at the European Society of Cardiology Heart Failure Congress in Athens, Greece
28 mai 2019 08h30 HE
|
MyoKardia, Inc.
First-in-Human Data for MYK-491 in Healthy Volunteers Demonstrated Well-Tolerated Increases in Cardiac Contractility Topline Results from Phase 2a Clinical Trial of MYK-491 in Patients with Stable...
MyoKardia Reports First Quarter 2019 Financial Results
09 mai 2019 16h05 HE
|
MyoKardia, Inc.
Announces Enrollment Completing in the Phase 2 MAVERICK-HCM Trial Company to Host Conference Call and Webcast Today at 4:30 p.m. ET (1:30 p.m. PT) SOUTH SAN FRANCISCO, Calif., May 09, 2019 ...
MyoKardia to Present at Bank of America Merrill Lynch 2019 Health Care Conference
08 mai 2019 16h10 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 08, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
MyoKardia Announces Inaugural MyoSeeds™ Research Grants Program Awardees
07 mai 2019 16h10 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 07, 2019 (GLOBE NEWSWIRE) -- MyoKardia, a clinical-stage biopharmaceutical company pioneering precision medicine for the treatment of serious cardiovascular...
MyoKardia to Report First Quarter 2019 Financial Results on Thursday, May 9, 2019
02 mai 2019 08h00 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., May 02, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq: MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment of...
Clinical Trial Results from MyoKardia’s Phase 2 PIONEER-HCM Study of Mavacamten Published in the Annals of Internal Medicine
30 avr. 2019 08h30 HE
|
MyoKardia, Inc.
Mavacamten is Being Developed to Treat the Most Common Inherited Form of Heart Disease, Hypertrophic Cardiomyopathy, for Which No Targeted Medical Therapies Exist Twelve-Week Treatment with...
MyoKardia Announces Pricing of Public Offering of Common Stock
26 mars 2019 18h45 HE
|
MyoKardia, Inc.
SOUTH SAN FRANCISCO, Calif., March 26, 2019 (GLOBE NEWSWIRE) -- MyoKardia, Inc. (Nasdaq:MYOK), a clinical-stage biopharmaceutical company pioneering a precision medicine approach for the treatment...